Viking Therapeutics Inc. (VKTX) recently announced promising initial outcomes from its trial of the investigational obesity medication VK2735. This disclosure, made during a presentation at the ObesityWeek conference, highlighted advancements in weight reduction with the company's new oral tablet formulation.
The findings indicated that higher dosages of the newly developed tablet led to more significant weight loss than previous versions. In particular, an early-stage study revealed that participants experienced a 6.8 percent reduction in body weight compared to the placebo over 28 days. Those administered a 100-milligram dose of VK2735 achieved an average weight loss of 8.2 percent after the same period.
The trial included approximately 92 participants who were given varying dosages of the experimental pill. Back in March, Viking reported encouraging outcomes from the initial Phase 1 study of VK2735, in which participants witnessed reductions in average body weight of up to 3.3 percent compared to the placebo following 28 days of treatment. Participants receiving a 40-milligram oral dose experienced a 5.3 percent body weight reduction within the same timeframe.
